Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Mild Cognitive Impairment: potential therapeutics].

H Allain1, D Bentue-Ferrer, S Belliard

  • 1Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes I, CS 34317, 35043 Rennes Cedex.

Revue Neurologique
|January 17, 2003
PubMed
Summary

Mild Cognitive Impairment (MCI) involves memory decline in individuals. Research is exploring drugs to manage MCI symptoms and prevent progression to Alzheimer's Disease (AD).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fault diagnosis for discrete events systems described by partially observed Petri nets.

ISA transactions·2021
Same author

Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: An MRI Study of 16 French Cases.

AJNR. American journal of neuroradiology·2018
Same author

<i>In vivo</i> XCT bone characterization of lattice structured implants fabricated by additive manufacturing.

Heliyon·2017
Same author

[Specificities of the logopenic variant of primary progressive aphasia].

Revue neurologique·2014
Same author

Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000-2001.

Acta neurologica Scandinavica·2014
Same author

A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease.

European journal of neurology·2013

Area of Science:

  • Neurology
  • Gerontology
  • Pharmacology

Background:

  • Mild Cognitive Impairment (MCI) signifies memory decline and attention issues in cognitively intact individuals.
  • MCI is observed in 12-15% of cases and may precede Alzheimer's Disease (AD).

Purpose of the Study:

  • To discuss potential pharmaceutical interventions for MCI.
  • To review ongoing clinical trials and future drug assessments for MCI management.

Main Methods:

  • Review of current research and clinical trial data for MCI treatments.
  • Assessment of drug pipelines for potential efficacy in MCI patients.

Main Results:

  • Several long-term clinical trials are investigating various drug classes including antioxidants, nootropics, and anticholinesterases.

Related Experiment Videos

  • New molecules are in development for future assessment in MCI patients.

    • Conclusions:

    • The development of drugs to normalize MCI symptoms or halt progression to AD is under active investigation.
    • Further research and clinical trials are essential to evaluate new therapeutic strategies for MCI.